DelveInsight’s, “Glioma Competitive Landscape 2023” report provides comprehensive insights about 200+ Glioma companies and 220+ drugs in Glioma Competitive landscape. It covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Competitive Landscape Report
- DelveInsight’s Glioma report depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies for Glioma treatment.
- The leading Glioma companies working in the market include Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals, Ever Supreme Bio Technology, Chia Tai Tianqing Pharmaceutical Group, CytoVac, and others.
- Promising Glioma therapies in the various stages of development include DS-1001b, Radiotherapy, Nimotuzumab, AP23573, Nimotuzumab, BLZ-100, LY2157299, Temozolomide, and others.
- December 2023: Daiichi Sankyo Co. Ltd announced a study of Phase 2 clinical trials for DS-1001b. This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
- December 2023: Day One Biopharmaceuticals Inc. announced a study of Phase 3 clinical trials for DAY101 and Chemotherapeutic Agent. This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
Request a sample and discover the recent advances in Glioma Drugs @ Glioma Competitive Landscape Report
The Glioma report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Glioma report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.
Glioma Overview
Glioma is the most common form of central nervous system (CNS) neoplasm that originates from glial cells. The three types of glial cells including astrocytes, oligodendrocytes, and ependymal cells are the site of origin for brain cancer or glioma. The type of tumors that initiate in astrocytes are called astrocytoma or Glioblastoma while those tumors that start in oligodendrocytes are referred to as oligodendrogliomas.
Find out more about Glioma Analytical Perspective: In-depth Commercial Assessment @ Glioma Collaboration Analysis by Companies
Glioma Companies and Therapies
- Bristol-Myers Squibb: Opdivo
- Orbus Therapeutics: Eflornithine
- Northwest Biotherapeutics: DCVax-L
- Medicenna Therapeutics: MDNA55
- Adastra Pharmaceuticals: Zotiraciclib
Glioma Competitive Landscape
The Glioma competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
Glioma Report Assessment
- Company Analysis
- Glioma Therapeutic Assessment
- Glioma Pipeline Assessment
- Inactive drugs assessment
- Glioma Unmet Needs
Learn more about the emerging Glioma Competitive Landscape @ Glioma Market Drivers and Barriers, Unmet Needs
Scope of the Glioma Competitive Landscape Report
- Coverage- Global
- Glioma Companies- Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals, Ever Supreme Bio Technology, Chia Tai Tianqing Pharmaceutical Group, CytoVac, and others.
- Glioma therapies- DS-1001b, Radiotherapy, Nimotuzumab, AP23573, Nimotuzumab, BLZ-100, LY2157299, Temozolomide, and others
- Glioma Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type
Dive deep into rich insights for new drugs for Glioma Product Developmental Activities, Visit @ Glioma Research and Development Activities
Table of Content
- Introduction
- Executive Summary
- Glioma: Overview
- Glioma -Analytical Perspective: In-depth Commercial Assessment
- Competitive Landscape
- Therapeutic Assessment
- Glioma: Company and Product Profiles (Marketed Therapies)
- Novartis
- Tafinlar + Mekinist
- Glioma: Company and Product Profiles (Pipeline Therapies)
- Late Stage Products (Phase III)
- Bristol-Myers Squibb
- Opdivo
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Medicenna Therapeutics
- MDNA55
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Onxeo
- AsiDNA
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Evgen Pharma
- SFX-01
- Drug profiles in the detailed report…..
- Inactive Products
- Glioma Unmet needs
- Glioma Market drivers and barriers
- Appendix
For further information on the Glioma Report @ Glioma Preclinical and Discovery Stage Products
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market